Sculptor Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Sculptor Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-386,000	Closed	-$1.58M	–	430
2025 Q4	$1.58M	Hold	386,000	–	–	0.02%	250
2025 Q3	$1.88M	Sell	386,000 -182,300	-32%	-$957K	0.02%	227
2025 Q2	$2.88M	Buy	+568,300	New	+$2.79M	0.04%	206
2024 Q3	–	Sell	-318,400	Closed	-$2.39M	–	364
2024 Q2	$2.39M	Hold	318,400	–	–	0.05%	138
2024 Q1	$3.17M	Buy	+318,400	New	+$3.55M	0.06%	115

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sculptor Capital's RXRX Position: Q1 2026 in Review

Sculptor Capital sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 386,000 shares — an estimated $1.58M sold.

Sculptor Capital first reported a position in RXRX in Q1 2024 and held it in 5 quarters. The position peaked at $3.17M in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Sculptor Capital reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Sculptor Capital sold 386,000 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.58M.
Sculptor Capital first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 5 quarters.
Sculptor Capital's Recursion Pharmaceuticals position peaked at $3.17M in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.